

THERMOGENESIS CORP
Form 425
December 20, 2013

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 20, 2013

THERMOGENESIS CORP.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or
organization)

000-16375
(Commission File
Number)

94-3018487
(I.R.S. Employer
Identification No.)

2711 Citrus Road
Rancho Cordova, California 95742
(Address and telephone number of principal executive offices) (Zip Code)

(916) 858-5100
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- ☒ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

99.1 Transcript for video titled “Video 1, Overview of TotipotentRX and Cesca Therapeutics”

99.2 Transcript for video titled “Video 2, Leveraging India’s World Class Clinical Infrastructure”

99.3 Transcript for video titled “Video 3, Leveraging ThermoGenesis’ Cell Processing Excellence at the Patient Bedside”

99.4 CEO Introduction Letter

99.5 Legal Disclaimer

- 2 -

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

THERMOGENESIS CORP.,
a Delaware Corporation

Dated: December 20, 2013 /s/ Dan T. Bessey
Dan T. Bessey
Chief Financial Officer

Exhibit Index

Item	Description
	99.1 Transcript for video titled “Video 1, Overview of TotipotentRX and Cesca Therapeutics”
	99.2 Transcript for video titled “Video 2, Leveraging India’s World Class Clinical Infrastructure”
99.3	Transcript for video titled “Video 3, Leveraging ThermoGenesis’ Cell Processing Excellence at the Patient Bedside”
	99.4 CEO Introduction Letter
	99.5 Legal Disclaimer